A Phase I/II Study of the Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Conditions:   Histologically or Cytologically Confirmed Pancreatic Cancer;   Unresectable or Borderline Resectable Pancreatic Cancer;   Pancreatic Neoplasms;   Pancreatic Cancer;   Metastatic Pancreatic Cancer Interventions:   Drug: M7824;   Drug: M9241;   Radiation: SBRT Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials